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iochemical experiments have shown that Smad6 and
Smad ubiquitin regulatory factor 1 (Smurf1) block the
signal transduction of bone morphogenetic proteins
(BMPs). However, their in vivo functions are largely unknown.
Here, we generated transgenic mice overexpressing Smad6
in chondrocytes. Smad6 transgenic mice showed postnatal
dwarﬁsm with osteopenia and inhibition of Smad1/5/8
phosphorylation in chondrocytes. Endochondral ossiﬁcation
during development in these mice was associated with
almost normal chondrocyte proliferation, signiﬁcantly
delayed chondrocyte hypertrophy, and thin trabecular bone.
The reduced population of hypertrophic chondrocytes after
B
 
birth seemed to be related to impaired bone growth and
formation. Organ culture of cartilage rudiments showed
that chondrocyte hypertrophy induced by BMP2 was inhib-
ited in cartilage prepared from Smad6 transgenic mice. We
then generated transgenic mice overexpressing Smurf1 in
chondrocytes. Abnormalities were undetectable in Smurf1
transgenic mice. Mating Smad6 and Smurf1 transgenic
mice produced double-transgenic pups with more delayed
endochondral ossiﬁcation than Smad6 transgenic mice.
These results provided evidence that Smurf1 supports
Smad6 function in vivo.
 
Introduction
 
Bone morphogenetic proteins (BMPs) were originally iden-
tified as secreted signaling molecules that could induce
ectopic endochondral bone formation when implanted
subcutaneously. Subsequent molecular cloning experiments
have revealed that the BMP family consists of various
molecules including the growth and differentiation factor
subfamily, and belongs to the TGF-
 
  
 
superfamily. BMP
family members have diverse biological activities during the
development of various organs and tissues, as well as during
embryonic axis determination (Hogan, 1996).
Members of the TGF-
 
 
 
 superfamily transduce their signals
through two types of serine/threonine kinase receptors, types
I and II (Heldin et al., 1997; Shi and Massague, 2003).
Upon ligand binding, type I and type II receptors form a
tetramer consisting of two pairs of type I and type II receptors.
Type II receptors phosphorylate type I receptors. Then, type
I receptors phosphorylate downstream targets such as Smads.
In vertebrates, seven type I receptors and five type II receptors
have been found so far. Among them, three type I receptors,
BMP type IA receptor (BMPR-IA, or activin receptor-like
kinase [ALK-3]), BMPR-IB (ALK-6), and ALK-2, mediate
BMP signaling. Smads are the major downstream targets of
type I receptors for TGF-
 
 
 
/BMP superfamily proteins
(Heldin et al., 1997). Eight Smads have been identified in
mammals and are classified into three subgroups. Receptor-
regulated Smads (R-Smads) are phosphorylated at SSXS
motifs at their COOH terminus by type I receptors. Smad1,
Smad5, and Smad8 are R-Smads that transduce BMP signals,
and Smad2 and Smad3 are responsible for TGF-
 
 
 
 and activin
signaling. Phosphorylated R-Smads form heteromers with
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the common-partner Smad (Smad4), and translocate into the
nucleus where they interact with transcriptional factors to
bind directly or indirectly to specific DNA sequences for the
activation of gene transcription.
BMP signaling is subject to delicate regulation at multiple
levels: extracellularly, at the membrane site, and intracellu-
larly (Balemans and Van Hul, 2002). In the extracellular
space, several molecules antagonize BMPs. Among these an-
tagonists, noggin is expressed in cartilage and binds to BMPs
and prevents them from interacting with their receptors. At
the intracellular level, inhibitory Smads, Smad6 and Smad7,
inhibit phosphorylation of R-Smads by competing with
R-Smads for binding to phosphorylated type I receptors. In
particular, Smad6 appears to inhibit BMP signaling, whereas
Smad7 associates stably with TGF-
 
 
 
 receptor and BMP re-
ceptor complexes and inhibits the TGF-
 
 
 
– or BMP-medi-
ated phosphorylation of R-Smads (Hanyu et al., 2001). In
addition, ubiquitin-dependent protein degradation plays key
roles in Smad signaling. Smad ubiquitin regulatory factor 1
(Smurf1) and Smurf2 induce the ubiquitination and degra-
dation of Smad1 and Smad5 (Zhu et al., 1999; Zhang et al.,
2001). Furthermore, Smurf1 and Smurf2 interact with
nuclear Smad7 and induce the nuclear export of Smad7.
Smurf–Smad7 complexes then associate with type I receptor
for TGF-
 
 
 
 and enhance its turnover (Kavsak et al., 2000;
Ebisawa et al., 2001). Recent biochemical analyses have
shown that Smurf1 binds to BMP type I receptors via Smad6
and Smad7, and that it induces the ubiquitination and degra-
dation of these receptors (Murakami et al., 2003). Thus,
Smad6 and Smurf1 cooperatively down-regulate BMP sig-
nals by degradation of R-Smads as well as BMP receptors.
However, the physiological function of Smurfs is unknown.
During development, the limb skeleton is formed through
endochondral bone formation (Erlebacher et al., 1995).
Mesenchymal cells initially undergo condensation followed
by differentiation of cells within these condensations into
chondrocytes. Chondrocytes then proliferate and produce
ECM to form primordial cartilage. Shortly after the primor-
dial cartilage formation, proliferating chondrocytes in the
central region of the cartilage undergo terminal differentia-
Figure 1. Postnatal dwarfism in Smad6 
transgenic mice. (A) Diagram of DNA 
constructs used to generate Smad6 
transgenic mice. Gene structure of 
Col11a2 is shown at top. Boxes indicate 
coding regions and solid lines denote 
noncoding sequences. A 1.6-kb DNA 
fragment covering the entire coding 
region of mouse Smad6 cDNA tagged 
with FLAG sequence at the 5  terminus 
was ligated to the promoter and 1st intron 
enhancer sequences of the Col11a2 gene. 
Bracket indicates SV40 splice cassette. 
(B) Normal and transgenic pups from lines 
138 and 139 at 3 wk of age. (C) RT-PCR 
analysis of Smad6 mRNA expression at 
16.5 d.p.c. (D and E) Temporal changes 
in crown–rump length (D) and weight (E) 
of wild-type and Smad6 transgenic mice 
from line 199 (n   12). (F–H) Length of 
humerus (F), femur (G), and tibia (H) in 
wild-type and Smad6 transgenic mice 
from line 199 at 3 wk of age (n   5). 
Error bars show means   SD. *, P   0.01 
between wild-type and transgenic mice 
as determined by t test. Bar (B), 3 cm. 
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tion to hypertrophic chondrocytes. Hypertrophic chondro-
cytes exit the cell cycle and synthesize an ECM that is differ-
ent in composition from that of proliferating cartilage. The
hypertrophic cartilage is invaded by blood vessels along with
osteoblasts, osteoclasts, and hematopoietic cells to form pri-
mary ossification centers. Within these centers, the hyper-
trophic cartilage matrix is degraded, hypertrophic chondro-
cytes die, and osteoblasts replace the disappearing cartilage
with trabecular bone (Olsen et al., 2000). Then, bone for-
mation and maintenance are performed by a balance be-
tween the new apposition of bony matrix by osteoblasts and
resorption by osteoclasts.
Smad proteins have been identified in growth plate carti-
lage (Flanders et al., 2001). In vitro analyses have shown that
Smad6 regulates the chondrocytic phenotype (Valcourt et al.,
2002; Nishihara et al., 2003). However, the physiological
roles of Smad6 and Smad signaling in normal endochondral
bone formation have not been determined. Here, we gener-
ated transgenic mice overexpressing Smad6 or Smurf1 in
chondrocytes under the control of the 
 
 
 
2(XI) collagen chain
gene (
 
Col11a2
 
) promoter/enhancer sequences. We found
that overexpression of Smad6 does not significantly affect
chondrocyte proliferation, but significantly delays chondro-
cyte hypertrophy, which may lead to postnatal dwarfism with
osteopenia. By using double-transgenic mice, we also found
that Smurf1 supports Smad6 function in vivo.
 
Results
 
Generation of Smad6 transgenic mouse lines
 
We ligated the Smad6 cDNA with a 5
 
 
 
 FLAG epitope
to 
 
Col11a2
 
 promoter/enhancer sequences to construct the
transgene 
 
Col11a2-Smad6
 
 (Fig. 1 A). Generation zero (G
 
0
 
)
embryos of Smad6 transgenic mice were initially killed, in
case Smad6 transgenic mice were lethal. 17 of 129 embryos
were genetically positive for the transgene. Smad6 transgenic
and normal embryos appeared similar. The Smad6 trans-
genic mice survived after birth, so several independent trans-
genic mouse lines could be established. The phenotypes of
all transgenic mouse lines were similar, with differences in
the degree of abnormalities between lines.
 
Postnatal dwarfism in Smad6 transgenic mice
 
1 wk after birth, the Smad6 transgenic mice started to de-
velop dwarfism (Fig. 1, B–H). Our data were collected from
three transgenic founders derived from microinjections,
transgenic pups with severe phenotypes generated from two
mosaic founders (lines 138 and 139), and transgenic off-
spring with mild phenotypes generated from two transgenic
founders (lines 165 and 199). Dwarfism was more severe in
the transgenic mice of line 139 than of line 138 (Fig. 1 B).
Phenotype severity closely correlated with transgene expres-
sion levels as shown by RT-PCR (Fig. 1 C). Quantitative
real-time RT-PCR using total RNAs extracted from limb
buds showed that the amount of Smad6 mRNAs of trans-
genic line 139 was threefold that of normal mice, and double
that of transgenic line 138. At 3 wk after birth, the average
crown–rump length of transgenic mice (line 199) was 
 
 
 
20%
shorter than that of normal mice (Fig. 1 D). Transgenic mice
(line 199) weighed an average of 30–40% less (Fig. 1 E), and
the average length of the skeletal components was 20–30%
shorter compared with normal littermates (Fig. 1, F–H).
 
Cartilage-specific expression of transgene in Smad6 
transgenic mice
 
Northern blotting demonstrated Smad6 expression in the
limb buds of transgenic mice. Transgene Smad6 mRNA was
Figure 2. Cartilage-specific expression of transgene in Smad6 
transgenic mice. (A) Northern blot hybridized with Smad6 probe. 
Bottom shows ethidium bromide–stained gel before transfer. 
(B) Protein expression of Smad6 transgene. Positive control consisted 
of lysates from COS7 cells transfected with expression construct 
FLAG-Smad6 (left lane). (C–L) Immunohistochemical analysis of 
humerus from normal (C, E, G, and I) and Smad6 (D, F, H, and J) 
transgenic mice at various stages of development using anti-Smad6 
antibody. Serial sections for I and J were stained with safranin O/fast 
green/iron hematoxylin (K and L). Arrow indicates endogenous Smad6 
mRNA. Half-arrow indicates Smad6 transgene mRNA. Open arrow 
represents FLAG-tagged Smad6 protein. Bars: (C and D) 100  m; 
(E and F) 200  m; (G–L) 500  m. 
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2 kb in length, which was smaller than endogenous
Smad6 mRNA due to shorter 5
 
 
 
 and 3
 
 
 
 untranslated regions
(Fig. 2 A). Immunoblotting demonstrated the expression of
a 70-kD FLAG-tagged Smad6 protein in limb buds of
Smad6 transgenic mice (Fig. 2 B, open arrow). Immunohis-
tochemistry using anti-Smad6 antibody showed more in-
tense signals for Smad6 proteins in forelimb chondrocytes of
Smad6 transgenic mice (Fig. 2, D, F, H, and J) than from
wild-type mice (Fig. 2, C, E, G, and I) from 13.0 through
18.5 days post coitus (d.p.c.).
 
Blockage of Smad signaling in cartilage of Smad6 
transgenic mice
 
We examined Smad signaling in chondrocytes by immuno-
histochemistry using an antibody that recognizes only phos-
phorylated forms of Smad1, Smad5, and Smad8. Phospho-
Smad1/5/8 immunoreactivity was reduced in transgenic
cartilage sections from 16.5 d.p.c. limbs (Fig. 3, B and D)
compared with the wild type (Fig. 3, A and C). We cultured
explants of metatarsal primordial cartilage from 15.0 d.p.c.
embryos. Recombinant human BMP2 (rhBMP2) proteins
were added to the culture media and explants were histolog-
ically analyzed 2 h later. rhBMP2 dramatically increased
phospho-Smad1/5/8 immunoreactivity in explants from
wild-type mice (Fig. 3, E and G), but not from Smad6
transgenic mice (Fig. 3, F and H). These results suggested
that Smad signaling was inhibited in the transgenic cartilage
by an excess of Smad6.
 
Osteopenia in Smad6 transgenic mice
 
We analyzed the bone structure of transgenic mice. Micro-
CT analysis of the humerus revealed that the primary spon-
giosa was significantly more hypoplastic and disorganized in
Smad6 transgenic mice (Fig. 4, B and D) than in normal lit-
termates (Fig. 4, A and C). The average bone volume per to-
tal tissue volume of primary spongiosa was 30–40% smaller
than that of normal littermates (Fig. 4 E).
Differences in bone formation were further examined by
bone histomorphometric analysis. Trabecular bone volume
was significantly decreased in Smad6 transgenic mice (Fig. 4
F). The osteoblast surface per bone surface in transgenic
mice was significantly decreased (Fig. 4 G). We analyzed dy-
namic changes in bone formation and mineralization by in-
jecting tetracycline and calcein at 2-d intervals. The distance
between the two consecutive labels was significantly de-
creased in transgenic mice (Fig. 4, H–J). The mineralization
surface was decreased, although not significantly (Fig. 4 K).
These data showed a significantly decreased bone formation
rate (Fig. 4 L). As for osteoclastic bone resorption, the osteo-
clast number per bone surface, osteoclast surface per bone
surface, and erosive surface per bone surface were signifi-
cantly increased (Fig. 4, M–O).
To elucidate the mechanism by which osteoclastic bone
resorption was activated in Smad6 transgenic mice, we per-
formed bone marrow cell culture and analyzed dexametha-
sone/parathyroid hormone-induced osteoclastogenesis. The
number of tartrate-resistant acid phosphatase (TRAP)–posi-
tive multinucleated cells in the culture prepared from trans-
genic mice was equivalent to that of normal mice (Fig. 4,
P–R). The resorption of hydroxyapatite by cultured osteo-
clast prepared from transgenic mice was essentially normal
(Fig. 4 S). Next, we examined osteoclast formation activi-
ties in spleen cell culture in the presence of RANK ligand.
RANK ligand–induced osteoclastogenesis of spleen cells
from Smad6 transgenic mice was normal, as indicated by the
number of TRAP-positive multinucleated cells and the re-
sorption of hydroxyapatite (unpublished data). These results
suggested that both osteoclast precursors and osteoclast-sup-
porting activities of osteoblast/stromal cells were normal in
the bone marrow of Smad6 transgenic mice.
 
Skeletal development of Smad6 transgenic mice
 
Because the transgene was expressed specifically in cartilage,
we analyzed the skeleton from earlier stages of development.
Whole-mount in situ hybridization using a type II collagen
gene (
 
Col2a1
 
) antisense cRNA probe showed that the pat-
tern and intensity of signals did not obviously differ between
Figure 3. Blockage of Smad signaling in cartilage of Smad6 
transgenic mice. (A–D) Immunohistochemistry of elbow joints in 
wild-type (A and C) and transgenic (B and D) mice at 16.5 d.p.c. 
Staining with hematoxylin and eosin (A and B). Serial sections of A 
and B were immunostained using anti-phospho-Smad1/5/8 antibody 
(C and D). (E–H) Immunohistochemistry of metatarsal cartilage 
explants at 15.0 d.p.c. before (E and F) and after exposure to rhBMP2 
for 2 h (G and H). Phospho-Smad1/5/8 immunoreactivity was not 
increased by rhBMP2 in sections of cartilage explants from Smad6 
transgenic mice (F and H) compared with those in wild-type mice 
(E and G). Bars: (A–D) 300  m; (E–H) 200  m. 
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Smad6 transgenic and normal mice at either 12.5 (Fig. 5, A
and B) or 13.0 (Fig. 5, C and D) d.p.c. This suggested that
mesenchymal condensation was essentially normal in the
transgenic mice. At 13.5 d.p.c., the size and shape of each
cartilaginous skeletal component stained with Alcian blue of
transgenic mice were essentially identical to those of normal
littermates (Fig. 5, E and F). The central regions of metatar-
sals were mineralized in normal mice as they were stained
with Alizarin red S, but not in transgenic mice at 16.5 d.p.c.
(Fig. 5, G and H, arrowheads) and at 18.5 d.p.c. (Fig. 5, I
and J, arrowheads). The size of mineralized tissue in the hu-
merus and femur was considerably smaller in transgenic
mice than in normal mice (Fig. 5, G and H, arrows). At 3
wk of age, skeleton of transgenic mice was much smaller
than that of normal mice (Fig. 5, K and L).
 
Delayed hypertrophy of chondrocytes in Smad6 
transgenic mice
 
We further examined endochondral bone formation by his-
tological means. At 13.5 d.p.c. when condensed mesen-
chymal cells differentiate into chondrocytes, chondrocytes
did not obviously differ histologically between normal and
transgenic mice (Fig. 6, A and B). At 14.5 d.p.c., prolifera-
tive chondrocytes exit the cell cycle and start terminal differ-
Figure 4. Osteopenia in Smad6 trans-
genic mice. (A–E) Micro-CT analysis of 
proximal humerus in 3-wk-old normal 
(A and C) and Smad6 transgenic (B and 
D) mice. Reconstructed coronal view 
(A and B) and reconstructed three-dimen-
sional image (C and D) of trabecular bone. 
(E) Trabecular bone volume per total 
tissue volume compared between normal 
and transgenic mice. (F–O) Bone histo-
morphometric analysis of fourth lumbar 
vertebral bodies at 4 wk of age. (F) Tra-
becular bone volume (BV/TV; bone vol-
ume over tissue volume), (G) osteoblast 
surface per bone surface (Ob.S/BS), (H) 
mineral apposition rate (MAR), (K) min-
eralizing surface per bone surface (MS/
BS), (L) bone-forming rate per bone 
surface (BFR/BS), (M) osteoclast num-
ber per bone surface (N.Oc/BS), (N) os-
teoclast surface per bone surface (Oc.S/
BS), and (O) eroded surface per bone 
surface (ES/BS) compared between nor-
mal and transgenic mice. Fluorescent 
micrograph of labeled mineralization 
fronts in normal (I) and Smad6 transgenic 
(J) mice. (P–S) Osteoclastogenesis of 
cultured bone marrow cells. Micro-
graph of cultured multinucleated cells 
stained with TRAP prepared from nor-
mal (P) and Smad6 transgenic (Q) mice. 
Number of TRAP-positive multinucle-
ated cells (R) and resorption of hy-
droxyapatite (S) were compared be-
tween normal and transgenic mice. Error 
bars show means   SD. *, P   0.01 be-
tween normal and transgenic mice as de-
termined by t test. Bars: (A–D, P, and Q) 
300  m; (I and J) 10  m. 
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entiation into hypertrophic chondrocytes at the center of
each skeletal component (Fig. 6 C). On the other hand,
transgenic cartilage from the humerus contained prolifera-
tive but not hypertrophic chondrocytes (Fig. 6 D). Hybrid-
ization in situ showed that proliferative chondrocytes in
Smad6 transgenic mice expressed 
 
Col2a1
 
 mRNA (Fig. 6 F),
like those of normal mice. Northern blotting of limb bud
extracts showed that expression levels of the Sox9 gene,
 
Col2a1
 
, and type IX collagen 
 
 
 
1 chain mRNAs were similar
between transgenic and normal mice at 13.5–19.5 d.p.c.
(unpublished data). However, the transgenic cartilage lacked
type X collagen–positive (Fig. 6 H) and osteopontin-positive
(Fig. 6 J) cells, whereas cartilage from normal mice expressed
these genes (Fig. 6, G and I). In addition, von Kossa staining
revealed mineralization in the normal (Fig. 6 K) but not in
the transgenic (Fig. 6 L) mouse humerus. At 16.5 d.p.c.,
normal mice formed ossification centers in the humerus
(Fig. 6 M). However, although a zone of hypertrophic chon-
drocytes was present in the transgenic humerus, an ossifica-
tion center had not formed (Fig. 6 N). At 18.5 d.p.c., the
transgenic skeletal element was composed of cartilage at
both ends and bone at the center, like the wild type (Fig. 6,
O and P). These results suggest that Smad6 overexpression
delayed chondrocyte hypertrophy and ossification by 
 
 
 
3 d
during development of the mouse humerus.
 
Normal chondrocyte proliferation and reduced 
population of hypertrophic chondrocytes in Smad6 
transgenic mice
 
For further analysis of chondrocyte proliferation in Smad6
transgenic mice, we performed BrdU labeling at embryonic
(Fig. 7, A and B) and postnatal (Fig. 7, C–F) stages. There
were not significant differences in BrdU labeling indexes be-
tween chondrocytes of normal and Smad6 transgenic mice
at 16.5 d.p.c. (Fig. 7 G) and at 3 wk of age (Fig. 7 H).
Once hypertrophic chondrocytes formed at later stages of
development, populations of hypertrophic chondrocytes
of transgenic mice did not significantly differ from those of
normal littermates (Fig. 7, I, J, and M). However, popula-
tions of hypertrophic chondrocytes in Smad6 transgenic
mice decreased after birth (Fig. 7, K and L). The mean
height of zones of hypertrophic chondrocytes was signifi-
cantly less than that of normal littermates at 3 wk after birth
(Fig. 7 N).
 
Chondrocyte hypertrophy induced by BMP2 was 
down-regulated in cartilage explants prepared from 
Smad6 transgenic mice
 
To investigate BMP signaling in chondrocytes, we organ
cultured primordial metatarsal cartilage at 15.0 d.p.c. Phase-
contrast microscopy could distinguish the zones of prolifera-
tive and mineralized hypertrophic cartilage in the cultures
(Fig. 8 A), which was confirmed by histology (Fig. 8, B and
C). At the start of culture, metatarsal rudiments from
Smad6 transgenic mice were indistinguishable from those of
normal mice (Fig. 8, D and E). After 4 d of culture in con-
trol medium, the length of hypertrophic cartilage in normal
rudiments was increased (Fig. 8 F), whereas transgenic rudi-
ments lacked hypertrophic cartilage (Fig. 8 G). Culture in
the presence of rhBMP2 resulted in excessive outgrowth of
the proliferative cartilage at both ends of the rudiments and
enhanced formation of a hypertrophic center in the normal
Figure 5. Skeletal development of Smad6 transgenic mice. (A–D) 
Whole-mount in situ hybridization using Col2a1 antisense cRNA 
probe at 12.5 (A and B) and 13.0 (C and D) d.p.c. (E–L) Alcian blue 
and Alizarin red S staining of whole skeleton of normal (E, G, I, and K) 
and transgenic (F, H, J, and L) mice at various stages of development. 
Arrowheads indicate metatarsals. Arrows show mineralized tissues 
in humerus and femur. Bars: (A–D) 200  m; (E–L) 2 mm. 
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Figure 6. Delayed hypertrophy of chondrocytes in Smad6 transgenic mice. Histology of humerus of normal (A, C, E, G, I, K, M, and O) and 
Smad6 transgenic (B, D, F, H, J, L, N, and P) mice at various stages of development visualized by hematoxylin and eosin (A and B), safranin 
O/fast green/iron hematoxylin (C, D, and M–P), and von Kossa (K and L) staining. Semi-serial sections to C and D were hybridized with cRNA 
probes for Col2a1 (E and F), Col10a1 (G and H), and osteopontin gene (I and J). p, Proliferative cartilage; h, hypertrophic cartilage; b, bone. 
Bars: (A and B) 200  m; (C–P) 500  m. 
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rudiments (Fig. 8 H). In transgenic rudiments incubated
with rhBMP2, proliferative cartilage expanded (Fig. 8 I) like
that of normal mice (Fig. 8 H), but formation of the hyper-
trophic center was limited (Fig. 8 I) compared with that of
normal mice (Fig. 8 H). These findings were confirmed by
morphometric analysis of the rudiments (Fig. 8, J and K),
indicating that Smad6 overexpression inhibited chondrocyte
hypertrophy induced by rhBMP2.
 
The overexpression of Smurf1 in Smad6/Smurf1 
double-transgenic mice enhanced phenotypes of 
Smad6 transgenic mice
 
To investigate in vivo function of Smurf1, we generated
transgenic mice overexpressing Smurf1 in chondrocytes. We
prepared the transgene construct by ligating Smurf1 cDNA
with a 5
 
 
 
 FLAG epitope to 
 
Col11a2
 
 promoter/enhancer
sequences (
 
Col11a2-Smurf1
 
; Fig. 9 A). Smurf1 transgenic
mice appeared normal in all respects, as they grew normally
after birth and were fertile. Northern blotting demonstrated
Smurf1 expression in transgenic limb buds (Fig. 9 B).
Transgenic 3-kb Smurf1 mRNA was shorter than endoge-
nous Smurf1 mRNA due to differences at both the 5
 
 
 
 and 3
 
 
 
untranslated regions. Exogenous rhBMP2 added to Smurf1
transgenic cartilage in organ cultures of metatarsal rudi-
ments at 15.0 d.p.c. caused proliferative cartilage outgrowth
and hypertrophic center formation as in normal mice. The
mean area of proliferative cartilage in Smurf1 transgenic ru-
diments (0.44 
 
 
 
 0.03 mm
 
2
 
) did not significantly differ from
that of normal littermates (0.47 
 
 
 
 0.07 mm
 
2
 
; 
 
n
 
 
 
 
 
 6, P 
 
 
 
0.08). The mean length of hypertrophic cartilage in Smurf1
transgenic rudiments (0.26 
 
 
 
 0.02 mm) also did not signifi-
cantly differ from that of normal littermates (0.26 
 
 
 
 0.01
mm; 
 
n
 
 
 
 
 
 6, P 
 
 
 
 0.75). These results suggest that Smurf1
overexpression does not significantly affect either chondro-
cyte proliferation or hypertrophy induced by rhBMP2.
We then produced transgenic offspring overexpressing
both Smad6 and Smurf1 in chondrocytes (Smad6/Smurf1
double-transgenic mice) by mating Smurf1 transgenic mice
with Smad6 transgenic mice of line 199 to test cooperative
function of Smad6 and Smurf1. The phenotypes of the dou-
ble-transgenic mice were similar to but more severe than
those of Smad6 transgenic mice. At 16.5 d.p.c., mineraliza-
tion was evident in the metatarsals of normal and Smurf1
transgenic mice (Fig. 9, C and D, arrowheads), but not in
Smad6 transgenic and Smad6/Smurf1 double-transgenic
mice (Fig. 9, E and F, arrowheads). The mineralized area in
 
Figure 7.
 
Normal chondrocyte proliferation and reduced population 
of hypertrophic chondrocytes in Smad6 transgenic mice.
 
 (A–D) 
Immunohistochemical detection of BrdU-labeled chondrocytes in 
proximal humerus. Proliferative chondrocytes of normal (A) and 
Smad6 transgenic (B) embryos at 16.5 d.p.c.; counterstained with 
hematoxylin (A and B). Growth plate cartilage of normal (C) and 
Smad6 transgenic (D) mice at 3 wk of age. (E and F) Serial sections 
to C and D were stained with hematoxylin and eosin. Numbers of 
BrdU-positive cells/mm
 
2
 
 cartilage compared between normal and 
transgenic mice at 16.5 d.p.c. (G) and at 3 wk of age (H). (I–L) Zone 
of hypertrophic chondrocytes of proximal humerus in normal (I and K) 
and Smad6 transgenic (J and L) mice. Staining with safranin O/fast 
green/iron hematoxylin at 18.5 d.p.c. (I and J). Staining with
hematoxylin and eosin (K and L). Heights of zone of hypertrophic 
chondrocytes were measured and compared between normal and 
transgenic mice at 17.0 d.p.c. (M) and at 3 wk of age (N). Error bars 
show means 
 
 
 
 SD. p, Proliferative cartilage; h, hypertrophic cartilage. 
*, P 
 
 
 
 0.001 between normal and transgenic mice as determined by 
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the femur was significantly shorter in Smad6 transgenic
mice than in normal mice. Furthermore, the mineralized
area in the femur was significantly shorter in Smad6/Smurf1
double-transgenic mice than in Smad6 transgenic mice.
(Fig. 9, C–G). Histological analysis revealed that ossification
was further delayed in the double-transgenic mice compared
with the Smad6 transgenic mice (Fig. 9, H and I). Labeling
cartilage with BrdU revealed little differences in chondrocyte
proliferation among normal littermates and the single- or
double-transgenic mice. The labeling indexes at 16.5 d.p.c.
were 7.66   1.51, 7.86   1.05, 7.65   1.12, and 7.31  
3.74 cells/0.01 mm
2 cartilage in normal littermates, Smurf1
transgenic, Smad6 transgenic, and Smad6/Smurf1 double-
transgenic mice, respectively (no significant difference; n  
5, P   0.05).
Discussion
Smad6 controls chondrocyte hypertrophy by down-
regulating BMP signals in endochondral ossification
Mice lacking Smad6 develop cardiovascular abnormalities
(Galvin et al., 2000). Ectopic endochondral bone forms in
the heart of mutant mice, suggesting that Smad6 plays cer-
tain roles in endochondral bone formation in vivo. How-
ever, the physiological roles of Smad6 and Smad signaling
in normal endochondral bone formation are poorly un-
derstood. In this work, we generated transgenic mice over-
expressing Smad6 in chondrocytes. Smad6 overexpression
resulted in a delayed chondrocyte hypertrophy and min-
eralization in endochondral ossification. Smad1/5/8 phos-
phorylation was inhibited in Smad6 transgenic cartilage,
suggesting that Smad signaling was impaired in these
mice.
Smad6 appears to block BMP signaling, whereas Smad7
blocks that of both TGF-  and BMP (Hanyu et al., 2001).
Skeletal mineralization is delayed and skeletal patterning is
defective in mice lacking growth and differentiation factor 5
(Storm et al., 1994), BMPR-IB (Yi et al., 2000), or BMP7
(Luo et al., 1995; Jena et al., 1997). The similarity of de-
layed mineralization between these mutant mice and Smad6
transgenic mice suggests that BMP signals are blocked by
Smad6 during endochondral ossification. This notion was
confirmed by our results that chondrocyte hypertrophy and
mineralization induced by rhBMP2 was inhibited in carti-
lage explants from Smad6 transgenic mice. Because the
phosphorylation of Smad1/5/8 induced by rhBMP2 was
inhibited in explants from Smad6 transgenic mice, we
concluded that Smad6 regulates chondrocyte hypertrophy
through the inhibition of Smad1/5/8 phosphorylation, thus
down-regulating BMP signaling in endochondral bone
formation.
The most fundamental abnormality during chondrocyte
differentiation in Smad6 transgenic mice was a delay in
chondrocyte hypertrophy in humeri at 14.5 d.p.c. This de-
lay was accompanied by the persistent expression of the
Col2a1 gene and the retarded expression of the type X col-
lagen gene (Col10a1). Extensive analyses in vitro have shown
that BMP signals promote chondrocyte hypertrophy, and
BMP-responsive cis-acting elements have been identified in
the promoter sequence of the Col10a1 gene (Volk et al.,
1998; Drissi et al., 2003). These in vitro analyses and our in
vivo results collectively suggest that Smad6 overexpression
blocks BMP signaling, thus preventing transcriptional acti-
vation of the Col10a1 gene.
Figure 8. Down-regulation of chondrocyte hypertrophy induced 
by rhBMP2 in cartilage explants by Smad6 overexpression. (A–C) 
Microscopic and histological appearance of normal mouse metatarsal 
rudiments cultured in the presence of rhBMP2. (A) Rudiments consist 
of bright gray areas at both ends and dark gray central areas under 
phase-contrast microscopy. (B) Histological section stained with 
safranin O shows that bright and dark gray areas correspond to 
proliferative and hypertrophic cartilage, respectively. (C) von Kossa 
staining shows that dark gray areas contain mineralized tissue. (D–I) 
Cultured metatarsal rudiments prepared from normal (D, F, and H) 
and Smad6 transgenic (E, G, and I) mice. (D and E) Rudiments at the 
start of culture. (F and G) Rudiments cultured for 4 d in control 
medium. (H and I) Rudiments cultured for 1 d in control medium 
followed by 3 d in medium containing rhBMP2. (J and K) Morpho-
metric analysis of metatarsal explant. Areas of proliferative cartilage 
and length of hypertrophic cartilage were measured for each rudiment. 
Error bars show means   SD (n   5). p, Proliferative cartilage; h, 
hypertrophic cartilage; m, mineralized hypertrophic cartilage; n.s., 
not significant. *, P   0.01 between normal and transgenic mice as 
determined by one-way analysis of variance (ANOVA) followed by 
Fisher’s PLSD test. Bars (A–I), 500  m.442 The Journal of Cell Biology | Volume 165, Number 3, 2004
Smad6 regulates endochondral ossification in 
cooperation with Smurf1
Smurf1 binds Smads 1 and 5 and promotes their degradation
(Zhu et al., 1999). Smurf1 and Smad6 form complexes and
inhibit BMP signaling through the ubiquitin-dependent deg-
radation of BMP receptors as well as of R-Smads (Murakami
et al., 2003). Smurf2 may also exhibit functions similar to
Smurf1. To examine the in vivo function of Smurf1, we gen-
erated transgenic mice expressing Smurf1 in chondrocytes
and did not find obvious abnormalities. These results sug-
gest that sufficient Smurf1 already exists in normal chondro-
cytes. When apparently normal Smurf1 transgenic mice were
mated with Smad6 transgenic mice, the endochondral ossifi-
cation of progenies overexpressing both Smad6 and Smurf1
was more delayed than in transgenic mice overexpressing
only Smad6. It is likely that the Smad6 transgenic mice have
far less Smurf1/2 than Smad6. In Smad6/Smurf1 double-
transgenic mice, Smurf1 derived from the transgene might
compensate for this shortage, thus supporting the activities of
a large amount of Smad6. When Smurf1 transgenic mice
were mated with those of the Smad6 transgenic line 165 in
which the expression level was low, the phenotypic severity
of the resultant double-transgenic progeny did not differ
from those of Smad6 transgenic mice of line 165 (unpub-
lished data). In Smad6 transgenic mice of this line, endoge-
nous Smurf1/2 fully supported the activities of endogenous
Smad6 and that derived from the transgene. From these lines
of discussion, the expression level of Smad6 appears to be
critical in the regulation of conversion from proliferative
chondrocytes to hypertrophic chondrocytes. Actually, the ex-
pression level of Smad6 is decreased in the transitional zone
between proliferative chondrocytes and hypertrophic chon-
drocytes (Flanders et al., 2001), suggesting that critical regu-
lation of Smad6 expression is responsible for this conversion.
The expression level of inhibitory Smads seems to be consis-
tently and strictly regulated through autoregulatory negative
feedback during signal transduction of the TGF- /BMP su-
perfamily because the inhibitory Smad mRNA is induced by
TGF-  stimulation (Heldin et al., 1997).
Postnatal dwarfism with osteopenia might be 
associated with the reduced zone of
hypertrophic chondrocytes
The most apparent phenotype of Smad6 transgenic mice
was postnatal dwarfism and osteopenia. Dynamic bone his-
tomorphometric analysis revealed that osteoblastic bone for-
mation decreased and that osteoclastic bone resorption in-
creased in Smad6 transgenic mice. However, results from
cultured bone marrow cells suggested normal osteoclast-sup-
Figure 9. Skeletal phenotypes are more severely disrupted in Smad6/
Smurf1 double-transgenic mice than in Smad6 transgenic mice. 
(A) DNA constructs used to generate Smurf1 transgenic mice. Gene 
structure of Col11a2 is shown at top. (B) Northern blot hybridized 
with Smurf1 probe. Left, wild-type; right, Smurf1 transgenic mice. 
Bottom shows ethidium bromide–stained gel before transfer. (C–F) 
Alcian blue and Alizarin red S staining of hindlimb skeleton of 
normal (C), Smurf1 transgenic (D), Smad6 transgenic (E), and Smad6/
Smurf1 double-transgenic (F) mice at 16.5 d.p.c. (G) Length of 
mineralized area in femur at 16.5 d.p.c. Length of tissue stained with 
Alizarin red S was measured. (H–J) Histology of tibia of normal (H), 
Smad6 transgenic (I), and Smad6/Smurf1 double-transgenic (J) mice 
at 16.5 d.p.c. Arrow shows endogenous Smurf1 mRNA. Half-arrow 
indicates Smurf1 transgene mRNA. Arrowheads indicate mineralized 
tissues in metatarsals. Error bars show means   SD (n   5). *, P   0.01 
between normal and Smad6 transgenic mice; **, P   0.01 between 
Smad6 transgenic and Smad6/Smurf1 double-transgenic mice as 
determined by one-way analysis of variance (ANOVA) followed by 
Fisher’s PLSD test. Bars (C–F and H–J), 0.5 mm.Role of Smad6/Smurf1 in endochondral ossification | Horiki et al. 443
porting activities of osteoblasts/stromal cells prepared from
Smad6 transgenic mice. These in vitro results suggest that
the increased in vivo osteoclastic bone resorption in trans-
genic mice was not due to an autonomous abnormality
within bone marrow cells. This notion was consistent with
the observation that the transgene was specifically expressed
in chondrocytes. We speculate that abnormal activities of os-
teoblasts and osteoclasts might be associated with the dys-
function in cartilage during endochondral bone formation.
However, we could not rigorously exclude leaky transgene
expression in cells in osteoblast lineage, and thus the possi-
bility that osteoblasts have a primary malfunction.
BrdU labeling revealed that proliferation of chondrocytes
in Smad6 transgenic mice was normal at the embryonic
stage and at the postnatal stage. Therefore, postnatal dwarf-
ism in Smad6 transgenic mice might develop through a
different mechanism from that in transgenic mice overex-
pressing activated FGF receptor 3 in cartilage, in which
chondrocyte proliferation is normal in embryos but postna-
tally decreased (Naski et al., 1998).
The onset of chondrocyte hypertrophy was delayed by  3 d
during the development of Smad6 transgenic mice. Once
the zone of hypertrophic chondrocytes formed, the height of
the zone of hypertrophic chondrocytes was essentially nor-
mal, suggesting that the population of hypertrophic chon-
drocytes is strictly regulated at late embryonic stages. We did
not determine which mechanism maintains the population
of hypertrophic chondrocytes in Smad6 transgenic embryos.
However, this population decreased in the transgenic mice
after birth. It is likely that reduced hypertrophic chondro-
cyte population lead to a deficiency in signals required for
coordination of growth and bone formation after birth. Hy-
pertrophic chondrocytes are known to produce various fac-
tors, including angiogenic factors (Karsenty and Wagner,
2002). A reduction in production of such factors may well
lead to dysfunction of osteoblast/osteoclast activities, thus
resulting in impaired bone growth and osteopenia.
It is also possible that abnormal chondrocyte hypertrophy
could result in the impaired structure of the ECM of hyper-
trophic cartilage. An impaired matrix might not provide a
suitable scaffold for osteoblasts and osteoclasts to replace car-
tilage with bone. This speculation remains to be examined.
Chondrocyte proliferation was not affected in Smad6 
transgenic mice
Previously, we generated transgenic mice expressing noggin
in chondrocytes under the control of the identical Col11a2
promoter/enhancer sequences used in this paper (Tsumaki
et al., 2002). We examined 62 G0 founder mouse embryos
for the noggin transgene, and 7 of them displayed a severe
phenotype and almost completely lacked cartilage formation
during development. On the other hand, 17 of 129 G0 em-
bryos were genetically positive for the Smad6 transgene, and
skeletal abnormalities were either relatively minor or almost
absent. Although we could not exclude the possibility that
the phenotypic difference between noggin and Smad6 trans-
genic mice might be related to the different level of expres-
sion of the transgenes, these results suggest that noggin tends
to affect cartilage more than Smad6 when expressed in chon-
drocytes in transgenic mice.
In addition, chondrocyte proliferation is inhibited in mice
lacking BMPR-IB (Yi et al., 2000) and in cartilage explants
cultured in the presence of noggin (Minina et al., 2001). Re-
ports have consistently indicated that BMP signaling stimu-
lates chondrocyte proliferation during endochondral bone
formation at the embryonic stages of transgenic mice overex-
pressing BMPs in cartilage (Tsumaki et al., 1999, 2002) and
in organ culture of cartilage rudiments in the presence of
BMPs (De Luca et al., 2001; Minina et al., 2001).
On the other hand, chondrocyte proliferation appeared
normal in Smad6 transgenic mice, as indicated by BrdU la-
beling. For explanation of the discrepancy between the find-
ings of chondrocyte proliferation obtained from Smad6
transgenic mice and those of other papers, we considered
four possibilities. First, we could not exclude the possibility
that the expression level of Smad6 transgene was not suffi-
cient to block BMP signaling completely, although im-
munohistochemical analysis showed strong expression of
the transgene (Fig. 2, C–J) Second, Smad signaling might
not be blocked by Smad6 alone. Certainly, phenotypes of
Smad6/Smurf1 double-transgenic mice were more severe
than that of Smad6 transgenic mice. However, it is still
milder than that of noggin transgenic mice, and chondro-
cyte proliferation remained normal, as indicated by BrdU la-
beling. Third, BMP signals might be mediated by signaling
pathways other than Smad proteins. In certain cell types,
various MAPKs have been reported to mediate BMP path-
ways (Iwasaki et al., 1999). Existence of such pathways
might account for the discrepancy between chondrocyte
proliferation in BMPR-IB–deficient mice and Smad6 trans-
genic mice. There is likelihood of the fourth possibility as
follows: BMPs and noggin are secreted and diffuse. In addi-
tion to direct binding to chondrocytes, these proteins might
exert indirect effects on chondrocytes. For example, BMPs
act on cells around cartilage, and in return these cells secrete
factors, affecting chondrocyte proliferation. Thus, the addi-
tion or overexpression of BMPs/noggin modulate chondro-
cyte proliferation directly and indirectly. On the other hand,
Smad6 overexpression in chondrocytes might block only the
direct effect of BMPs on chondrocytes.
In conclusion, our data on inhibition of endochondral
bone formation in Smad6 and Smurf1 transgenic mice sug-
gest a role for Smad signaling in skeletogenesis and growth.
By down-regulating Smad1/5/8 phosphorylation and BMP
signals, Smad6 plays an important role in regulation of
chondrocyte hypertrophy and synergistically cooperates with
Smurf1 in vivo.
Materials and methods
Construction of the transgene
The  2(XI) collagen gene–based expression vector, 742lacZInt, contains
the Col11a2 promoter ( 742 to  380), an SV40 RNA splice site, the
 -galactosidase reporter gene, the SV40 polyadenylation signal, and 2.3
kb of the first intron sequence of Col11a2 as an enhancer (Tsumaki et al.,
1996). To create a Smad6 transgene, a 1.5-kb DNA fragment covering the
entire coding region of mouse Smad6 cDNA tagged with a FLAG sequence
at the NH2 terminus was prepared. The FLAG-tagged Smad6 cDNA was
cloned into the NotI sites of 742lacZInt expression vectors by replacing the
 -galactosidase gene to create Col11a2-Smad6. For the Smurf1 transgene,
a FLAG-tagged Smurf1 cDNA was cloned into NotI sites of the expres-
sion vectors 742lacZInt by replacing the  -galactosidase gene to create
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Generation of transgenic mice
The plasmids Col11a2-Smad6 and Col11a2-Smurf1 were digested with
EcoRI and PstI to release the inserts. Transgenic mice were produced by
microinjecting each of the inserts into the pronuclei of fertilized eggs from
F1 hybrid mice (C57BL/6x DBA) as described previously (Tsumaki et al.,
1996). Transgenic embryos were identified by PCR assays of genomic
DNA extracted from the placenta or skin. Genomic DNA was amplified by
transgene-specific PCR using primers derived from mouse Smad6 cDNA
(5 -CAAGATCGGTTTTGGCATACTG-3 ) and from the SV40 poly(A) signal
region (5 -TCACTGCATTCTAGTTGTGGTTTGTCC-3 ) to amplify a 411-bp
product for Smad6 transgenic mice. To discriminate Smurf1 transgenic
mice, genomic DNA was amplified by transgene-specific PCR using prim-
ers derived from mouse Smurf1 cDNA (5 -ATGGACTACAAGGACGAT-
GATGACAAGG-3  and 5 -AGGGGCTGGTTCCTCCATGAAGCAG-3 ) to
amplify a 570-bp product. Smad6/Smurf1 double-transgenic pups were
generated by mating Smad6 and Smurf1 transgenic mice.
Staining of the skeleton
Mice were dissected and fixed in 100% ethanol overnight, and then
stained with Alcian blue followed by Alizarin red S solution according to
standard protocols (Peters, 1977).
Micro CT analysis and bone mass measurement
The humeri from 5-wk-old transgenic mice and normal littermates were
dissected and analyzed using a micro-focus X-ray CT system (SMX-100CT-
SV; Shimadzu). The region extending from the proximal growth plate to
the metaphyseal part of the humerus on 350 slices was scanned at a width
of 6.75  m per slice. The data were reconstructed to produce images of
the humerus using 3-D visualization and measurement software (Vay Tek,
Inc.). Bone mass was quantified by selecting 90 consecutive slices distal to
the proximal growth plate (0.6 mm in length). Trabecular parameters in the
metaphysis were determined using image analysis software (TRI/3D-BON;
RATOC).
Histology and immunohistochemical staining
Embryos were dissected using a stereomicroscope (model SMZ645; Nikon),
fixed in 4% PFA, processed, and embedded in paraffin. Serial sections were
stained with hematoxylin and eosin, with safranin O/fast green/iron hema-
toxylin, or by the von Kossa reaction. Dynamic histomorphometric indices
were determined by double-fluorescence labeling in vertebral bodies.
4-wk-old normal and transgenic mice were administered i.p. with tetracy-
cline (20 mg/kg body weight; Sigma-Aldrich), followed by calcein label (10
mg/kg body weight; Wako Chemicals) 2 d later. After 24 h, the mice were
killed. Bones were fixed with ethanol and embedded in methylmethacry-
late. Sections were cut and viewed using a fluorescence microscope
(Eclipse E1000; Nikon). The Niigata Bone Science Institute (Niigata, Japan)
performed histomorphometric analyses. Immunohistochemistry proceeded
using a rabbit pAb against Smad6 (1:200 dilution; Zymed Laboratories) and
a rabbit pAb against phospho-Smad1/5/8 (1:200 dilution; Cell Signaling
Technology). Immune complexes were detected using streptavidin-peroxi-
dase staining and Histofine SAB-PO kits (Nichirei). Images were acquired
using a microscope (Eclipse E1000; Nikon) with a digital camera system
(DXM1200; Nikon).
BrdU staining
Pregnant mice bearing 16.5 d.p.c. embryos and 3-wk-old mice were i.p.
injected with BrdU labeling reagent (10  l/g body weight; Zymed Labora-
tories). 2 h later, the mice were killed. Embryonic limb buds and tibia of
the 3-wk-old mice were dissected and sectioned. Incorporated BrdU was
detected using a BrdU staining kit (Zymed Laboratories) to distinguish ac-
tively proliferating cells. Tissue sections were measured using a microme-
ter, and the average number of BrdU-positive cells/mm
2 cartilage   SD
was calculated.
Northern hybridization and real-time quantitative RT-PCR
Total RNA extracted from the limb buds of 14.5–18.5 d.p.c. transgenic and
normal embryos using RNeasy Mini Kits (QIAGEN) was fractionated by
electrophoresis through formaldehyde agarose gels and transferred onto
Nytran
® membranes (Schleicher & Schuell Bioscience). Complementary
DNAs (cDNAs) were labeled with [
32P]dCTP using Prime-it
® II kits (Strat-
agene). The membranes were hybridized with 
32P-labeled Smad6 cDNA
and rehybridized with 
32P-labeled probes for mouse  1(II) collagen,  1(IX)
collagen, and Sox9.
Total RNAs were digested with DNase to eliminate any contaminating
genomic DNA before real-time quantitative RT-PCR. 2  g of total RNA
was reverse transcribed into first-strand cDNA using OmniScript
® reverse
transcriptase (QIAGEN) and an oligo(dT)12-18 primer. The PCR amplifica-
tion proceeded in 20  l containing 1  l of cDNA, 2  l of SYBER Green™
Master Mix (QIAGEN), and 10 pmol of primers specific for Smad6
(5 -GATCCCCAAGCCAGACAGT-3  and 5 -AGCCTCTTGAGCAGCGC-
GAGTA-3 ) to generate a 126-bp product (GenBank/EMBL/DDBJ acces-
sion no. NM008542). The cDNA was amplified by 35 cycles using a Light-
Cycler
® quick system (Roche) according to the following protocol: 94 C for
15 s, 60 C for 20 s, and 72 C for 6 s, each with a temperature transition
rate of 20 C, according to the manufacturer’s instructions.
In situ hybridization
Digoxigenin-11 UTP-labeled single-strand RNA probes were prepared us-
ing a DIG RNA labeling kit (Boehringer) according to the manufacturer’s
instructions. We generated antisense and sense probes using  1(II) col-
lagen,  1(X) collagen, and osteopontin cDNAs. Hybridization proceeded
as described previously (Hirota et al., 1992; Conlon and Herrmann, 1993).
A Genius detection system (Boehringer) detected signals according to the
manufacturer’s instructions.
Immunoprecipitation and Western blotting
Limb buds of 14.5 d.p.c transgenic and normal embryos were lysed with
RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, and 10 mM DTT) supplemented with
protease and phosphatase inhibitor cocktails (Sigma-Aldrich). The positive
control consisted of COS7 cells transfected with the expression construct
FLAG-Smad6 that was also lysed with RIPA buffer. The cell lysates were
incubated with anti-Smad6 antibody (Zymed Laboratories) for 3 h at 4 C
followed by an incubation with protein G–agarose beads (Roche) for 3 h at
4 C. After five washes with lysis buffer (20 mM Hepes, 150 mM NaCl,
10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, and 100  M orthovanadate),
1  SDS sample buffer was added to the agarose beads. The samples were
incubated for 5 min at 95 C, fractionated by 10% SDS-PAGE, transferred
onto nitrocellulose membranes (Bio-Rad Laboratories), and Western blot-
ted against anti-FLAG M2 mAb (Sigma-Aldrich). Immunocomplex bands
were visualized using the ECL Western blotting detection system (Amer-
sham Biosciences).
Bone marrow cell culture
Osteoclast formation and bone resorbing activity were determined using
the modified method described in Azuma et al. (2000). In brief, bone mar-
row cells prepared from the femurs and tibias of 10-wk-old transgenic
mice or wild-type control mice were suspended in  -modified essential
medium containing 10% FBS, and were cultured in 48-well plates (10
6
cells/0.5 ml per well) for 7 d in the presence of 0.1  M dexamethasone
(Sigma-Aldrich) and 0.01  M recombinant human parathyroid hormone
(Peptide Institute, Inc.). Cells were then fixed and stained for TRAP using a
TRAP staining kit (Hokudo) according to the manufacturer’s recommenda-
tion. The number of multinucleated TRAP-positive cells with more than
three nuclei was counted under a microscope (Eclipse TE300; Nikon). To
examine calcified matrix resorption activity, 5   10
5 cells were cultured in
16-well hydroxyapatite-coated slides (Osteologic; Becton Dickinson) for
14 d, and the resorption area was calculated by computer-assisted image
analysis.
Metatarsal explant culture
Metatarsal rudiments were cultured as described previously (Haaijman et
al., 1997). Metatarsal rudiments were dissected from transgenic and nor-
mal embryos at 15.0 d.p.c. and cultured in  -modified essential medium
without nucleosides (Invitrogen), supplemented with 0.05 mg/ml ascorbic
acid (Sigma-Aldrich), 0.3 mg/ml L-glutamine (Merck), 0.05 mg/ml genta-
mycin (Invitrogen), 0.25 mg/ml Fungizone
® (Invitrogen), 1 mM  -glycero-
phosphate (Merck), and 0.2% FBS (GIBCO BRL) in a humidified atmo-
sphere of 5% CO2 in air at 37 C. 1 d after starting the cultures, the
rudiments were incubated in 400  l of the same medium containing 500
ng/ml of rhBMP2 (Yamanouchi Pharmaceutical Co., Ltd.) or without
rhBMP2 for a further 3 d. For immunohistochemical analysis using anti-
phosphorylated Smad1/5/8, rudiments were sectioned before and after a
2-h incubation with rhBMP2. Images of rudiments obtained under in-
verted phase-contrast microscopy were analyzed morphometrically (Eclipse
TE300; Nikon). Areas of proliferative cartilage and length of hypertrophic
cartilage were measured using NIH Image software (National Institutes of
Health, Bethesda, MD).
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